8-K: Nektar Reports Q3 2025 Results, Advances Key Drug Candidates

Nektar Therapeutics reported third quarter 2025 financial results, highlighting a decrease in revenue and net loss, alongside significant clinical progress for rezpegaldesleukin.

Summary

• Revenue in the third quarter of 2025 was $11.8 million, a decrease from $24.1 million in the third quarter of 2024, primarily due to the sale of the Huntsville manufacturing facility in December 2024.
• Net loss for the third quarter of 2025 was $35.5 million, or $1.87 basic and diluted loss per share, compared to a net loss of $37.1 million, or $2.66 basic and diluted loss per share, in the third quarter of 2024.
• Cash and investments in marketable securities stood at $270.2 million on September 30, 2025, an increase from $269.1 million on December 31, 2024.
• The company successfully raised $107.2 million in net proceeds from a secondary offering closed on July 2, 2025, and $34.3 million in net proceeds from an at-the-market (ATM) offering during Q3 2025, with an additional $38.3 million raised from the ATM offering in October 2025.
• Nektar expects its cash and investments in marketable securities to support operations into the second quarter of 2027.
• Significant progress was made with rezpegaldesleukin, including emerging data from the REZOLVE-AD study demonstrating a highly differentiated profile in moderate-to-severe atopic dermatitis and potential for co-morbid asthma.
• The U.S. Food and Drug Administration (FDA) granted Fast Track designation for rezpegaldesleukin for the treatment of severe-to-very-severe alopecia areata in July 2025.
• Topline data for rezpegaldesleukin in patients with severe-to-very-severe alopecia areata is expected to be reported in December 2025.

Sentiment

Score: 7

Explanation: While revenue decreased due to a strategic asset sale, the company significantly improved its cash position through capital raises and extended its cash runway. Clinical progress for rezpegaldesleukin, including Fast Track designation and promising data, indicates positive momentum for its lead pipeline asset, outweighing the revenue decline.

Positives

• Cash and investments in marketable securities increased to $270.2 million as of September 30, 2025, from $269.1 million on December 31, 2024.
• The company's cash runway is expected to support operations into the second quarter of 2027.
• Successful capital raises generated $107.2 million net from a secondary offering and $34.3 million net from an ATM offering in Q3 2025, with an additional $38.3 million net from ATM in October 2025.
• Net loss decreased to $35.5 million in Q3 2025 from $37.1 million in Q3 2024, and basic and diluted loss per share improved to $1.87 from $2.66.
• Total operating costs and expenses decreased to $43.5 million in Q3 2025 from $58.5 million in Q3 2024, driven by the elimination of cost of goods sold and reduced R&D and G&A expenses.
• Rezpegaldesleukin's REZOLVE-AD study shows emerging data demonstrating a highly differentiated profile for atopic dermatitis, including potential efficacy in co-morbid asthma.
• The FDA granted Fast Track designation for rezpegaldesleukin for severe-to-very-severe alopecia areata.
• Nektar's rezpegaldesleukin data were referenced in the background documents from the Nobel Committee for discoveries establishing FOXP3-positive Tregs as essential for peripheral immune tolerance.

Negatives

• Revenue significantly decreased to $11.8 million in Q3 2025 from $24.1 million in Q3 2024, primarily due to the sale of the Huntsville manufacturing facility.
• The company reported a net loss of $35.5 million for Q3 2025 and $128.0 million for the first nine months of 2025.
• Non-cash losses from the equity method investment in Gannet BioChem amounted to $0.5 million in Q3 2025 and $7.4 million for the first nine months of 2025.

Risks

• Statements regarding the therapeutic potential and future development plans for drug candidates (rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422, and NKTR-255) are based on preclinical and clinical findings and observations and are subject to change.
• Investigational agents are subject to substantial risks, including negative safety and efficacy findings in future clinical studies, despite positive findings in earlier studies.
• Drug candidates in clinical development have a high risk of failure, which can unexpectedly occur at any stage prior to regulatory approval.
• Data reported from ongoing clinical trials are interim and the final results may change based on continuing observations.
• The timing of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay/failure in obtaining regulatory approval.
• A Fast Track designation does not increase the likelihood that rezpegaldesleukin will receive marketing approval in the United States.
• Patents may not issue from patent applications, issued patents may not be enforceable, or additional intellectual property licenses from third parties may be required.
• Other important risks and uncertainties are set forth in the company's Quarterly Report on Form 10-Q filed with the SEC on August 8, 2025.

Future Outlook

Nektar expects its cash and investments in marketable securities to support operations into the second quarter of 2027. The company anticipates presenting new findings from the REZOLVE-AD study at the ACAAI Scientific Meeting on November 8, 2025, and reporting topline data for rezpegaldesleukin in severe-to-very-severe alopecia areata in December 2025.

Management Comments

• "We have made tremendous progress advancing rezpegaldesleukin, and the emerging data from the REZOLVE-AD study continue to demonstrate a highly differentiated profile for this first-in-class, novel regulatory T cell mechanism in moderate-to-severe atopic dermatitis."
• "We will present important new findings from REZOLVE-AD this weekend at the ACAAI Scientific Meeting highlighting the potential of rezpegaldesleukin to treat atopic dermatitis and co-morbid asthma, which occurs in about 25% of atopic dermatitis patients."
• "These compelling data give rezpegaldesleukin a unique position in the competitive landscape as this efficacy signal has not been observed with other biologic mechanisms recently approved or in advanced development."
• "We look forward to reporting in December the topline data for rezpegaldesleukin in patients with severe-to-very-severe alopecia areata, a chronic auto-immune condition that greatly impacts quality of life and mental health for these patients."

Industry Context

Nektar's focus on rezpegaldesleukin, a novel regulatory T cell stimulator, positions it in the competitive landscape of autoimmune and chronic inflammatory diseases, particularly atopic dermatitis and alopecia areata. The company highlights the unique efficacy signal observed in co-morbid asthma, differentiating it from other biologics. The reference to the Nobel Prize for FOXP3-positive Tregs underscores the scientific relevance of Nektar's mechanism of action in immune tolerance, potentially enhancing its standing in the immunology field.

Comparison to Industry Standards

• Rezpegaldesleukin's efficacy signal in co-morbid asthma has not been observed with other biologic mechanisms recently approved or in advanced development, suggesting a unique competitive advantage in the atopic dermatitis market.
• The Nobel Prize in Physiology or Medicine referencing rezpegaldesleukin data for discoveries establishing FOXP3-positive Tregs as essential for peripheral immune tolerance validates the scientific foundation of Nektar's lead candidate, aligning it with cutting-edge immunological research.

Stakeholder Impact

• Shareholders: Positive impact from extended cash runway and successful capital raises, reducing immediate dilution concerns. Potential for significant value creation if rezpegaldesleukin clinical trials are successful. Negative impact from continued net losses and revenue decline.
• Patients: Potential positive impact from the advancement of rezpegaldesleukin for atopic dermatitis and alopecia areata, offering new treatment options for severe conditions.
• Employees: Continued operations and clinical progress suggest stability, but ongoing cost management could imply efficiency drives.

Next Steps

• Present new findings from REZOLVE-AD at the ACAAI Scientific Meeting on November 8, 2025.
• Report topline data for rezpegaldesleukin in severe-to-very-severe alopecia areata in December 2025.
• Continue development of rezpegaldesleukin in atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus.
• Continue development of preclinical bivalent TNFR2 antibody and bispecific programs (NKTR-0165, NKTR-0166), and modified CSF protein (NKTR-422).
• Continue evaluation of NKTR-255 in ongoing clinical trials with partners.

Key Dates

Recommendation

While Nektar Therapeutics has significantly bolstered its cash position and extended its runway, and rezpegaldesleukin shows promising clinical data and received Fast Track designation, the company remains in a clinical-stage phase with no product sales revenue. The future success hinges heavily on the upcoming topline data for alopecia areata in December and continued positive development of its pipeline. The stock carries inherent high risk typical of biotechnology companies awaiting pivotal clinical outcomes and regulatory approvals. A 'hold' recommendation is appropriate for investors monitoring these critical near-term catalysts, acknowledging both the potential upside from clinical success and the ongoing financial losses and development risks.

Keywords

Nektar Therapeutics, NKTR, Biotechnology, Clinical-stage, Rezpegaldesleukin, Atopic Dermatitis, Alopecia Areata, Autoimmune Disease, Regulatory T cell, Financial Results, Q3 2025, Drug Development, Fast Track Designation, SEC Filing